WhatsApp Channel Join Now
Telegram Group Join Now
| Relevance: General Studies Paper II — Health Sector & Government Policies; GS Paper III — Science & Technology (Indigenous Vaccines & Diagnostics) | Source: ICMR PrevenTB Trial, BMJ, 2026 |
| A century after the first BCG vaccine, Tuberculosis (TB) still kills more Indians than any other infectious disease. The ICMR PrevenTB trial in the BMJ shows that two homegrown vaccines — VPM1002 and Immuvac — can cut Extrapulmonary TB by ~50%, with even stronger gains in children. The lesson is decisive: India must stop waiting for a perfect vaccine and deploy good-enough tools to hit its 2025 elimination target. |
1 · Background — the disease and its burden
| Tuberculosis (TB) is caused by Mycobacterium tuberculosis. Pulmonary TB (PTB) attacks the lungs and drives transmission; Extrapulmonary TB (EPTB) affects other organs (spine, brain, lymph nodes) — harder to detect, often fatal. Latent TB is an asymptomatic carrier state that can later turn active. |
- India’s load: Incidence of 200–300 per 100,000; the global “elimination” threshold is just 10–20 per 100,000.
- National goal: India aims to eliminate TB by 2025, five years ahead of the UN SDG target of 2030.
- Strategic anchor: The National TB Elimination Programme (NTEP) operates on four pillars — Detect, Treat, Prevent, Build.
- The unfinished story: No effective vaccine exists for adolescents and adults; BCG protects only infants.
2 · The four-layer elimination playbook
|
Layer 1 · Detect
Smart diagnostics
Indigenous TrueNat molecular test and AI-enabled chest X-ray screening catch subclinical and early-stage TB in the field.
|
Layer 2 · Prevent
Treat latent TB
Short-course preventive therapy (TPT) for household contacts and PLHIV stops latent cases progressing to active disease.
|
|
Layer 3 · Vaccinate
VPM1002 & Immuvac
VPM1002 — 50.4% efficacy vs EPTB overall; 64.6% in children 6–14. Immuvac — over 60% vs EPTB in children 6–10.
|
Layer 4 · Nourish
Low BMI = low immunity
PrevenTB showed reduced vaccine efficacy in underweight patients. Ni-kshay Poshan Yojana provides ₹1,000/month via DBT to plug this gap.
|
3 · Core analysis
A. Why the “perfect vaccine” hunt has failed
- Single-target trap: Most past trials chased only Pulmonary TB, missing the equally deadly Extrapulmonary form.
- Cost of waiting: Millions die while the “ideal” trial is repeated; LMICs cannot afford perfectionism.
B. The PrevenTB shift
- EPTB targeting: A 50% cut in EPTB cases means major drops in suffering, disability and out-of-pocket spending.
- Child protection: Vaccines worked best in the 6–14 age group — perfect for school-based delivery.
- Logistical advantage: VPM1002 is single-dose on a modified BCG platform — cheap, cold-chain friendly, scalable.
C. The structural enablers
- Atmanirbhar science: Adopting the indigenous TrueNat test ahead of WHO pre-qualification shows India can lead, not follow.
- Community ownership: The PM TB Mukt Bharat Abhiyaan converts elimination into a Jan Andolan through Ni-kshay Mitras.
- Health equity link: TB is concentrated in low-BMI, low-income households — making nutritional support a clinical, not charitable, intervention.
4 · Way forward
| Integrate VPM1002 & Immuvac into NTEP. Target school-age children and household contacts of TB patients first — the populations where efficacy is highest. |
| Use the rural health backbone. Deliver Ni-kshay Poshan Yojana baskets and patient tracking via ASHA workers, ANMs and Gram Panchayats; auto-link adherence to the Ni-kshay portal. |
| Scale indigenous diagnostics. Replicate the TrueNat model — back homegrown molecular and AI-based screening tools with assured public procurement. |
| Mainstream community ownership. Expand the Ni-kshay Mitra network so every notified TB patient has a “buddy” providing food, work and emotional support. |
| India’s TB story cannot end with a single miracle drug. The way out is a multi-layered defence — smart detection, latent treatment, moderately effective vaccines and assured nutrition — delivered by an empowered rural health workforce. Done together, these tools can convert elimination by 2025 from slogan into reality. |
| UPSC Value Box | ||||||||||||||||
|
| Quick Revision |
- TB caused by Mycobacterium tuberculosis; spreads via respiratory droplets.
- India’s TB incidence — 200–300 per 100,000; elimination threshold — 10–20 per 100,000.
- India’s TB elimination goal — 2025; UN SDG global target — 2030.
- NTEP — renamed from RNTCP in 2020; four pillars: Detect, Treat, Prevent, Build.
- VPM1002 by SIIPL — 50.4% efficacy vs EPTB; 64.6% in children 6–14 (ICMR PrevenTB trial).
- Immuvac by Cadila — over 60% efficacy vs EPTB in children 6–10.
- Ni-kshay Poshan Yojana — ₹1,000/month via DBT for notified TB patients.
- TrueNat — indigenous molecular TB test adopted before WHO pre-qualification.
| Mains Practice Question |
| How can state governments better leverage decentralised rural healthcare networks — including ASHA workers and Gram Panchayats — to ensure uninterrupted nutritional support and continuous patient tracking for those with latent or active Tuberculosis? Discuss in the light of India’s 2025 elimination target. (15 marks · 250 words) |
Structure hint:
Introduction — Anchor with 2025 elimination goal and the ICMR PrevenTB findings.
Body Part 1 — Role of ASHAs/ANMs in case detection, drug delivery, adherence tracking.
Body Part 2 — Role of Gram Panchayats — Ni-kshay Mitra mobilisation, hygiene, nutrition baskets.
Body Part 3 — Digital backbone — Ni-kshay portal, DBT for NPY, AI-enabled screening.
Way Forward — Layered defence: diagnostics + TPT + indigenous vaccines + nutrition + community.
Introduction — Anchor with 2025 elimination goal and the ICMR PrevenTB findings.
Body Part 1 — Role of ASHAs/ANMs in case detection, drug delivery, adherence tracking.
Body Part 2 — Role of Gram Panchayats — Ni-kshay Mitra mobilisation, hygiene, nutrition baskets.
Body Part 3 — Digital backbone — Ni-kshay portal, DBT for NPY, AI-enabled screening.
Way Forward — Layered defence: diagnostics + TPT + indigenous vaccines + nutrition + community.
Must mention:
NTEP & 2025 goal ·
VPM1002 & Immuvac ·
Ni-kshay Poshan Yojana ·
ASHA & Gram Panchayats ·
TrueNat
NTEP & 2025 goal ·
VPM1002 & Immuvac ·
Ni-kshay Poshan Yojana ·
ASHA & Gram Panchayats ·
TrueNat
Conclusion hint: Conclude that India’s TB victory will come not from a miracle vaccine but from layered, locally owned, nutrition-anchored care — turning every Panchayat into a frontline of elimination.
Share This Story, Choose Your Platform!
Start Yours at Ajmal IAS – with Mentorship StrategyDisciplineClarityResults that Drives Success
Your dream deserves this moment — begin it here.